Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel WG, Hanrath P, Mügge A, Klein HU, Schmidt-Lucke JA. Schmidt-Lucke C, et al. Among authors: hanrath p. Thromb Res. 2007;119(1):27-34. doi: 10.1016/j.thromres.2005.11.016. Epub 2006 Jan 27. Thromb Res. 2007. PMID: 16443257 Clinical Trial.
Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Stellbrink C, et al. Among authors: hanrath p. Circulation. 2004 Mar 2;109(8):997-1003. doi: 10.1161/01.CIR.0000120509.64740.DC. Epub 2004 Feb 16. Circulation. 2004. PMID: 14967716 Clinical Trial.
Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion--the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; Anticoagulation in Cardioversion using Enoxaparin Study Group. Stellbrink C, et al. Among authors: hanrath p. Card Electrophysiol Rev. 2003 Dec;7(4):382-6. doi: 10.1023/B:CEPR.0000023145.54503.a2. Card Electrophysiol Rev. 2003. PMID: 15071260
Low molecular weight heparin for prevention of thromboembolic complications in cardioversion--rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
Stellbrink C, Hanrath P, Nixdorff U, Hofmann T, Lehmacher W, Kühle K, Fetsch T, Grewe R, Schmidt-Lucke JA; Anticoagulation in Cardioversion using Enoxaparin Study Group. Stellbrink C, et al. Among authors: hanrath p. Z Kardiol. 2002 Mar;91(3):249-54. doi: 10.1007/s003920200019. Z Kardiol. 2002. PMID: 12001541 Clinical Trial.
A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.
Radke PW, Figulla HR, Drexler H, Klues HG, Mügge A, Silber S, Daniel W, Schmeisser A, Reifart N, Motz W, Büttner HJ, Fischer D, Ortlepp JR, Schaefers K, Hoffmann R, Hanrath P; AACHEN Trial Investigators. Radke PW, et al. Among authors: hanrath p. Am Heart J. 2006 Oct;152(4):761.e1-6. doi: 10.1016/j.ahj.2006.07.003. Am Heart J. 2006. PMID: 16996855 Clinical Trial.
506 results